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Abstract: In recent years, the reports on using nonsteroidal anti-inflammatory drugs (NSAIDs) 
for cancer prevention and treatment have been on the rise. In 2017, the US Preventive Services 
Working Group issued primary prevention guidelines on the use of NSAIDs, especially aspirin, 
for cardiovascular disease and colorectal cancer, and formally established the role and status of 
aspirin in cancer prevention. However, the mechanism of NSAIDs on preventing cancer is still 
not clear. In this paper, the progress of the application of NSAIDs, especially aspirin, in the 
prevention and treatment of tumors in recent years is summarized, and new ideas and directions 
for the follow-up study are also discussed.
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Introduction
In 1897, German chemist Felix Hoffmann successfully applied salicylic acid and acetic 
anhydride to synthesize acetyl salicylic acid (acetylated salicylic acid) and obtained 
excellent effects in the treatment of rheumatoid arthritis for his father. This drug was 
named aspirin. Since then, this anti-inflammatory drug has been officially accepted 
in clinical practice, making it the most widely used antipyretic, analgesic and anti-
inflammatory drug in the world. In addition to treatment, aspirin has been utilized as 
a standard preparation for the evaluation of other drugs. The molecular structure of 
aspirin is simple but used in vivo aspirin has shown a variety of effects over the years. 
It has been used as analgesic, antipyretic, anti-inflammatory and antirheumatic treat-
ment in cardiovascular and cerebrovascular thrombosis. While its side effects cannot be 
ignored, especially long-term use of aspirin can lead to increased risk of gastrointestinal 
bleeding, increased uric acid, allergic asthma, coagulation inhibition amongst others.1 
In recent years, different types of NSAIDs have been developed and applied to clinical 
treatment, but among all NSAIDs, aspirin still seems to be the best and first choice.2
Some large epidemiological studies have displayed that aspirin shows great effect 
in the primary and secondary prevention of cancer and in a variety of malignant tumor 
treatments (especially in colon cancer, stomach cancer etc.).3–6 In May 2009, a meta-
analysis of aspirin in the prevention of colorectal cancer (CRC) and other cancers 
in recent years7 reported that regular administration of aspirin is associated with the 
reduction of the incidence of cancer. This attracted scientific interest and posed the 
question: could anti-inflammatory drugs be used for the prevention and treatment of 
the tumor? There are some problems raised in this hypothesis, such as how to avoid the 
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gastrointestinal bleeding caused by long-term use of aspirin 
and the optimal dosage of aspirin. Therefore using aspirin in 
cancer prevention and treatment is still very controversial. 
In 2012, Rothwell8 indicated that regular administration of 
aspirin (≥75 mg/daily) could reduce the incidence of adeno-
carcinoma, CRC, and lung cancer, inhibit tumor metastases, 
and improve the survival rate of cancer patients. Additionally, 
they hypothesized that aspirin could inhibit tumor metastasis 
by eliminating platelet aggregation.
Early theories indicated that anti-inflammatory drugs 
could remove inflammatory factors in the  surrounding 
inflammatory microenvironment of the tumor, so that the 
tumor cells can be directly exposed to immune cells, and 
then immune cells can function through immune recognition 
to achieve the role of cleaning up tumor cells. It is known 
that the body can self-recover after short-term inflamma-
tory response, and this is a normal body self-protection 
mechanism, but long-term chronic inflammation may lead 
to cancer. Colotta et al9 proposed that tumors are caused 
by inflammation factors (IL-1, IL-6, IL-12, IL-17, TNF-α, 
TGF-β, etc.) assembling and the reactive oxygen species 
(ROS) produced by inflammatory infiltrating cells in the 
inflammatory microenvironment causing DNA damage 
(such as P53 gene mutation) and further induce normal 
cell carcinogenesis. Based on this, Okada et al10 created 
gp91phox gene knockout mouse implanted with or without 
degenerated fibro sarcoma cells (QR cells) and wild-type 
mouse macrophages. Compared to the gene knockout 
mouse, mouse implanted with wild-type mouse macro-
phages increased frequency of tumor development, and 
showed macrophage-driven ROS participated in the devel-
opment of tumors. Amino guanidine is a broad inhibitor 
of inducible nitric oxide synthase, and its regulation can 
partially and significantly inhibit the transformation of 
degenerating QR cells into fibrosarcoma cells, therefore 
Futoshi Okada et al10 speculated that in addition to ROS 
there was nitrous oxide (NO) involved in the process of 
tumor deterioration. In addition, the inflammatory cyto-
kines, chemokines (IL family) and NK cells can accumulate 
in the surrounding microenvironment of the tumor, and 
mediate the growth and metastasis of tumor cells (related to 
the upregulation of the expression of vascular growth factor 
in the surrounding tumor microenvironment).11,12 Addition-
ally, the inflammatory factor and histamine can increase 
the permeability of the vessel wall and the lymphatic wall, 
and assist the distal metastasis of the tumor.13 This article 
was therefore regarded as the cornerstone of the researches.
Aspirin used in primary tumor 
prevention
A great number of large epidemiological studies found that 
long-term use of low-dose aspirin (75–300 mg/daily) can 
effectively inhibit a variety of cancer incidence, malignant 
cancer metastasis rate, and provide patients with a high 
survival rate. In 2012, Rothwell et al14 conducted a meta-
analysis of the six trials of daily low-dose aspirin in primary 
prevention (35,535 participants) and pointed out that the 
regular administration of low-dose aspirin (75–300 mg/
daily) for more than 3 years can reduce cancer risk by 24% 
(324 vs 421 cases; OR = 0.76, 95% CI 0.66–0.88, P=0.0003). 
In addition, the aspirin group reduced the risk of CRC within 
20 years in six randomized trials and 26 case–control stud-
ies. At the same time, the risk of esophageal cancer, gastric 
cancer, cholangiocarcinoma and breast cancer in the aspirin 
group was significantly decreased. Rothwell et al15 analyzed 
five large randomized clinical trials which examined the 
effects of aspirin (75 mg/daily or more) on tumors. The 
results of the analysis showed that aspirin could reduce the 
incidence of distant metastases by 36% and reduce the risk 
of cancer-specific mortality by 50% compared with the 
control group. For patients with adenocarcinoma, the risk 
of morbidity can be reduced by 46%. In patients with no 
metastatic adenocarcinoma at the time of initial diagnosis, 
the use of aspirin in the subsequent long-term observation 
can reduce the associated cancer metastasis rate by 70%. In 
2014, Cuzick et al16 also concluded that taking low doses of 
aspirin (30–100 mg/daily) for 10 years can reduce the risks 
of gastric cancer, esophageal cancer, and CRC by 30%. Liao 
et al17 found regular use of aspirin (twice a week or more, 
standard dose of 325 mg aspirin tablets) after diagnosis, 
compared with wild-type PIK3CA cancer patients, mutant 
PIK3CA CRC patients can obtain more benefits, and this 
once again determined the value of aspirin in primary pre-
vention of CRC. A prospective study showed that among the 
registered 130,251 healthy subjects, after a 32-year follow-
up survey, 27,985 people had cancer (20,414 women).18 
Those who regularly take aspirin (0.5–1.5 standard aspirin 
tablets/week, 163 mg to 488 mg) for at least 6 years would 
reduce the overall risk of cancer by 3%, gastrointestinal can-
cer incidences reduce, including CRC (19% lower risk) and 
gastroesophageal cancer, but the risks of non-gastrointestinal 
cancer (such as breast cancer, advanced prostate cancer, lung 
cancer, etc.) were not significantly reduced. Importantly, ret-
rospective epidemiological studies have shown that low-dose 
aspirin (75 mg/day) is more effective in reducing morbidity 
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and mortality associated with CRC than high-dose aspirin 
(325–1200 mg/day).8
In April 2016, the USPSTF19 reviewed a number of large 
randomized controlled trials (RCTs) in the use of aspirin to 
prevent cancer, and found that taking aspirin for 3.6–10.1 
years showed no significant difference in the overall cancer 
mortality and incidence between the aspirin group and the 
normal control group. The 20-year mortality rate of CRC 
was significantly lower in the aspirin group (four RCTs, 
RR=0.67), and the incidence of CRC was reduced for those 
taking aspirin for 10–19 years (three RCTs, total number of 
cases 47464, relative risk [RR]=0.60). In view of this, the 
USPSTF eventually issued aspirin as a guide for cardio-
vascular disease (CVD) and primary prevention of CRC, 
and ultimately recommended that: adults aged 50–69 years, 
10% or greater 10-year CVD risk, are not at increased risk 
of bleeding, have a life expectancy of at least 10 years, and 
are willing to take low-dose aspirin (75 mg/daily) for at least 
10 years, should consider taking low-dose aspirin to prevent 
CVD and CRC. The working group here considered the 
 benefits of the various protocols that have been demonstrated 
in primary prevention trials, including doses of 75 and 100 
mg per day and doses of 100 and 325 mg aspirin every day. 
The daily dose of 75 mg seems to be as effective as the higher 
dose (325 mg). However, the risk of gastrointestinal bleeding 
may increase with the increased doses. Comprehensive con-
sideration is given that aspirin should be taken at 50–325 mg/
day. Meanwhile, the guidelines also emphasize the need for 
trade-offs and individualization of aspirin-induced bleeding 
and other risks and benefits. It is worth mentioning that in the 
USA, the most commonly prescribed dose is 81 mg per day. 
In addition, we have summarized the main recommendations 
of the USPSTF in Table 1.
Antitumor mechanism of non-
steroidal anti-inflammatory drugs 
(NSAIDs)
Inhibition of COX-2
Most of the NSAIDs are thought to act as tumor suppres-
sors by inhibiting cyclooxygenase-COX.20 COX is known 
Table 1 Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer in the USA: clinical summary19
Population Recommendation Recommended instructions Treatment and 
dosage
Balance of benefits 
and harms
Risk assessment
Adults 
younger than 
50 years
No 
recommendation. 
grade:I
The current evidence is 
insufficient to assess the balance 
of benefits and harms of initiating 
aspirin use for the primary 
prevention of CVD and CRC in 
adults younger than 50 years
A reasonable 
approach consistent 
with the evidence is 
to prescribe 81 mg/d 
(the most commonly 
prescribed dose in 
the USA), and assess 
CVD and bleeding risk 
factors starting at age 
50 y and periodically 
thereafter, as well 
as when CVD and 
bleeding risk factors 
are first detected or 
change.
The benefits of 
aspirin use outweigh 
the increased risk 
for bleeding by a 
moderate amount.
Primary risk factors 
for CVD are older 
age, male sex, race/
ethnicity, abnormal 
lipid levels, high blood 
pressure, diabetes, and 
smoking. Risk factors 
for GI bleeding with 
aspirin use include 
higher aspirin dose and 
longer duration of use, 
history of GI ulcers or 
upper GI pain, bleeding 
disorders, renal failure 
severe liver disease, and 
thrombocytopenia.
Adults aged 
50–59 years 
with a≥10% 
10-years 
CVD risk
Initiate low-dose 
aspirin use. Grade:B
Persons who are not at 
increased risk for bleeding, have 
a life expectancy of at least 10 
years, and are willing to take 
low-dose aspirin daily for at least 
10 years
The benefits of 
aspirin use outweigh 
the increased risk for 
bleeding by a small 
amount.
Adults aged 
60–69 years 
with a ≥10% 
10-years 
CVD risk
The decision to 
initiate low-aspirin 
use is an individual 
one. Grade:C
Persons who are not at 
increased risk for bleeding, have 
a life expectancy of at least 10 
years, and are willing to take 
low-dose aspirin daily for at 
least 10 years are more likely 
to benefit. Persons who place 
a higher value on the potential 
benefits than the potential harms 
may choose to initiate low-dose 
aspirin. (C recommendation)
The evidence 
on aspirin use is 
insufficient and the 
balance of benefits 
and harms cannot be 
determined.
Adults aged 
70 years or 
older
No 
recommendation. 
grade:I
The current evidence is 
insufficient to assess the balance 
of benefits and harms of initiating 
aspirin use for the primary 
prevention of CVD and CRC in 
adults aged 70 years or older.
The evidence 
on aspirin use is 
insufficient and the 
balance of benefits 
and harms cannot be 
determined.
Abbreviations: CVD, cardiovascular disease; CRC, colorectal cancer; GI, gastrointestinal.
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to convert arachidonic acid to prostaglandins (PGs), and 
the PGs overexpression are thought to be early events in 
a variety of oncogenic events. COX has three structural 
subtypes, structural COX-1 and inducible COX-2 (selectiv-
ity), COX-3 (found in the nervous system appears late in 
the inflammatory response).21,22 COX-1 is mainly present 
in normal tissue cells and catalyzes the production of PGs 
that maintain normal physiological function. COX-2 is a 
membrane-bound protein. In normal physiological status, 
the majority of tissue cells do not express COX-2; but in 
inflammation, tumor and other pathological conditions, due 
to inflammatory substances and carcinogenic substances 
such as the inflammatory mediators induced, COX-2 shows 
an increasing expression, and participates in a variety of 
pathophysiological processes, causing canceration (large 
number of COX-2-dependent genes are involved in this 
tumorigenesis process).23,24 Krysan et al25 found that COX-2 
is usually upregulated in carcinoma in situ and non-small-
cell lung cancer. Chen et al26 showed that the high expression 
of COX-2 in tumor tissue upregulated the expression of 
bcl-2 and thus played the role of an antiapoptotic effect of 
tumor cells. In addition, COX-2 and PG overexpression in 
chronic inflammation suggest that PGs produced by COX-2 
catalysis can induce neovascularization to a certain extent 
and provide nutrition for tumor survival and  proliferation.27 
Finally, the COX-2 can affect upregulation of matrix metal-
loproteinase-2 expression which then promotes tumor 
invasion and metastasis.28 Recent studies have shown that 
the specific COX-2 enzyme inhibitor celecoxib (a NSAID) 
can effectively inhibit a variety of tumor cell proliferation 
and promote apoptosis on Raji cells, SK-N-SH cells and 
K562 cells in vitro.29–31 In addition, Harris et al32 conducted 
a case–control study of NSAID in 489 lung cancer patients 
and 978 control subjects. The results showed that a daily 
intake of aspirin or ibuprofen for at least 2 years reduces the 
relative risk of lung cancer by 68% (P<0.01). The detection 
of COX-2 in patients also suggested that patients taking 
NSAID significantly reduced the content. These results, 
with molecular evidence suggested that NSAID intake may 
prevent cancer by blocking COX-2 expression.
Induced tumor cell apoptosis
Bcl-2 gene inhibits apoptosis predominantly in the follow-
ing three ways: 1) Bcl-2 can change the mitochondrial thiol 
reduction state to control the membrane potential and regulate 
apoptosis; 2) Bcl-2 can regulate the mitochondrial membrane 
permeability of some apoptotic protein precursors; 3) Bcl-2 
can locate the apoptotic protein precursor Apaf-1 to the mito-
chondrial membrane so that it cannot play a role in apoptosis.
Yang et al and Xu et al33,34 used aspirin to treat human 
small cell lung cancer A549 cells, ovarian cancer SK-OV-3 
cells and showed the expression of bcl-2 gene decreased and 
the expression of bax gene increased. Kim35 found that strong 
NSAIDs such as naproxen used on culture bladder cancer cells 
caused significant cell apoptosis, which was mainly due to 
the downregulation of bcl-2 gene and the upregulation of bax 
gene. In addition, Bank et al36 found that NSAIDs sulindac 
acid can degrade antiapoptotic protein bcl-XL, block bcl-XL 
antagonism of bax, make pro-apoptotic protein bax activation 
caspase cascade reaction, then activate the cell apoptosis pro-
gram. Raza et al37 found that amino salicylic acid can increase 
the production of intracellular ROS, reduce intracellular glu-
tathione storage, and inhibit mitochondrial respiratory chain 
enzyme complex, electron transport chain complex Body I, 
electron transport chain complex IV, mitochondrial matrix 
enzyme, cis-aconitase and other enzyme activity. The mito-
chondrial permeability changes can then lead to the synthesis 
of ATP being blocked, bcl-2 expression downregulated, and 
the release of cytochrome C will eventually trigger apoptosis. 
Furthermore, celecoxib can increase the wild-type p53 gene 
cancer overexpressing the p53 protein.38 The upregulation of 
p53 protein expression could further upregulate the expression 
of p53up-regulated modulator of apoptosis (PUMA) protein, 
which is the p53 gene downstream positive regulator. PUMA 
encodes the BH3-only protein of the bcl-2 family, whereas the 
BH3-only protein is a key factor in the initiation of apoptosis 
by the p53 pathway.
Downregulation of EGFR expression
Recently, Dong et al39 found that in 80% of patients with 
colorectal cancer EGFR overexpression occurred, but it can 
be downregulated by regular use of aspirin. Similarly, they 
noted that EGFR and COX-2 were co-located in patients with 
familial multiple adenomas and that COX-2 overexpression 
triggers proto-oncogene c-Jun-dependent transcription fac-
tors which bind to the EGFR promoter activation of protein-1 
and can further promote the accumulation of EGFR cells in 
cells and promote their transformation to malignant.
Protect and repair DNA damage
Oxidative stress plays an important role in the development of 
various diseases such as cancer, cardiovascular disease, etc40,41 
and can damage nucleic acid, protein, membrane and other 
cell elements. Banti et al42 mentioned that aspirin counteracts 
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exogenous bacterial infections by inhibiting the production 
of peroxides, and oxygen radicals produced by bacteria, and 
can therefore cause great damage to cellular DNA. Chen et 
al43 confirmed that aspirin can inhibit the formation of nucleic 
acid cleavage and hydroxyl radicals caused by peroxynitrite, 
which play a role in protecting DNA. Goel et al44 found that 
aspirin could induce high expression of DNA mismatch 
repair proteins hMLH1, hMSH2, hMSH6 and hPMS2 in 
colon cancer cells, and the high expression of hMLH1 and 
hMSH2 could induce tumor cell apoptosis. Dibra et al45 found 
that aspirin can induce X-ray repair of cross-complementary 
gene 3 (XRCC3) and its protein expression, thus promoting 
DNA self-healing.
The general antitumor mechanism of NSAIDs is sum-
marized in Table 2.
The new thinking on the apparent 
phenomenon
Individual differences bring non-
universality
A recent study in 2012 set out aspirin as a research boom 
in CRC secondary prevention. Liao et al17 retrospectively 
analyzed 964 patients with CRC and found that CRC-
related mortality was significantly reduced (RR=0.18) and 
the overall survival extended (RR =0.54) in patients with 
CRC who had been diagnosed with aspirin-treated PIK3CA 
mutations. In contrast, in PIK3CA wild-type patients, regular 
aspirin administration (twice a week or more, standard dose 
of 325 mg aspirin tablets) after diagnosis did not improve 
CRC patients specific survival (RR=0.96) or overall survival 
(RR=0.94). In addition, some studies46,47 have shown that 
patients with 15-PGDH (15-hydroxyprogesterone dehydro-
genase) and antigen-specific HLA-1 high expression in colon 
cancer can achieve more benefits in aspirin therapy (twice 
a week or more, standard dose of 325 mg aspirin tablets). 
Based on this, whether PIK3CA, 15-PGDH and HLA-1 can 
be used as key molecular biomarkers in the treatment of CRC 
is worthy of consideration.
NSAIDs prevents cancer from escaping 
immune surveillance
In 2015, Zelenay et al48 demonstrated that skin cancer, breast 
cancer and CRC cells often produce large amounts of PG E2 
(PGE2), which can attenuate the immune system’s normal 
response to diseased cells and help cancer cells to hide. 
This process allows the tumor to grow rapidly, and therefore 
explains why some immunotherapy has difficulty in achiev-
ing the desired effect. Aspirin is a kind of COX inhibitor, 
which can inhibit the synthesis of PGE2 to achieve the effect 
of re-awakening the immune system. Therefore, compared 
with the use of immunotherapy alone, the combination of 
immunotherapy with aspirin or other COX inhibitors can 
significantly reduce the growth of CRC or melanoma in 
mice. In addition, a study showed that platelets can also help 
tumor cells escape the immune system.49 In vivo platelet-
specific Glycoprotein A Repetitions Predominant (GARP) 
can activate platelet-derived or non-platelet-derived TGFβ, 
and GARP-TGFβ complex can effectively reduce the activ-
ity of T-cell activity at the physiological level. Thus most 
tumor cells can escape the clearance of the immune system, 
and the use of platelet antagonists will significantly improve 
the killing of tumor cells by the immune system. Therefore, 
the administration of COX inhibitor or platelet antagonists 
simultaneously with the patient’s immunotherapy can make 
cancer immunotherapy more effective and may become a 
new treatment with great potential.
Table 2 Traditional pathway of NSAIDs inhibiting tumors
NSAIDs Target Pathway Result
Aspirin Downregulate COX-2 expression26,28 Downregulation of bcl-2 expression Cell apoptosis
Downregulation of mmp-2 expression Reduce tumor cell invasion
Aspirin/naproxen Downregulation of bcl-2 expression and up-
regulation of bax expression33–35
Caspase cascade reaction Cell apoptosis
Sulindac acid Degrade antiapoptotic protein bcl-XL36 Pro-apoptotic protein bax activation caspase 
cascade reaction
Cell apoptosis
Amino salicylic 
acid
Increase reactive oxygen species37 The mitochondrial permeability changes; bcl-2 
expression down regulated
Cell apoptosis
Celecoxib Increase p53 gene expression38 Upregulation of PUMA and BH3-only 
expression
Cell apoptosis by the p53 
pathway
Aspirin Upregulation of hMLH1, hMSH2, hMSH6 and hPMS2 expression44 Promote DNA self-healing
Upregulation of XRCC3 expression45
Abbreviations: COX-2, cyclooxygenase-2; NSAIDs, nonsteroidal anti-inflammatory drugs; XRCC3, X-ray repair of cross-complementary gene 3.
 
Ca
nc
er
 M
an
ag
em
en
t a
nd
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
3.
53
.1
24
.2
 o
n 
16
-O
ct
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Cancer Management and Research 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4636
Zhang et al
Aspirin, platelet, tumor
Recent reports show that patients with a high blood platelet 
count are significantly more likely to develop cancer than 
those with a low blood platelet count, suggesting that tumor 
development may be associated with platelets.50 It is known 
that platelets, in addition to coagulation, play a role in the 
formation of new blood vessels.51 This effect is usually ben-
eficial, such as the formation of a new clot after injury, and the 
need for new blood vessels to regulate blood flow. However, 
the same effect will also help the tumor growth. Platelets 
can enhance the invasiveness of cancer cells,49 promote 
epithelial-mesenchymal transition (EMT) transformation,52 
and contribute to the deterioration of cancer to a large extent. 
In addition, cancer as a long-term chronic injury process 
will inevitably produce various mechanical damage etc. and 
promote the self-aggregation of platelets in the cancer site. 
There is already evidence that platelets can be spontaneously 
recruited to colon cancer cells in patients with colon cancer,53 
which will undoubtedly greatly increase the progression of 
cancer. So we speculate that use of platelet antagonists can 
effectively slow down the progression of cancer. Lichtenberger 
et al54 indicated that aspirin can inhibit the activity of COX-1 
enzyme, control the number of circulating platelets and their 
activity levels, and therefore block the interaction between 
platelets and cancer cells. They used platelet co-culture of 
human and murine colon cancer cell layers with two differ-
ent aspirin preparations (normal aspirin and combination of 
phosphatidylcholine-specific aspirin) and found that platelets 
can significantly promote tumor cell proliferation and enhance 
its ability to migrate, while the use of aspirin can significantly 
decline the effect, and the effect of special aspirin (aspirin 
and phosphatidylcholine mixture) had increased efficacy. 
Other previous studies55 used platelets as a carrier to deliver 
PD-L1 antibody to the tumor site to achieve targeted killing 
of tumor cells and suggested that the role of platelets in the 
development of tumors is not absolute. Therefore, changing 
the traditional thoughts on cancer treatment would make us 
gain more benefits in the fight against tumors.
Aspirin against cancer by slowing up the 
mutation accumulates
It is known that tumorigenesis is caused by long-term accu-
mulation of genetic mutations. Kostadinov et al56 suggested 
that aspirin can prevent cancer by slowing the accumulation 
of DNA mutations in abnormal cells in precancerous lesions. 
They analyzed 13 biopsy samples from patients with Barrett’s 
esophagus and conducted a 6–19 years follow-up studies. In 
the “observational crossover” studied, some patients began 
taking aspirin daily initially for several years and then stopped 
taking it, while others took aspirin until the end of the obser-
vation. The biopsy results showed that patients who did not 
use aspirin showed more than 10 times faster accumulations 
of gene mutations than those who used aspirin long term.
Different forms of NSAIDs may have 
different effects
In addition to traditional formulations of NSAIDs for the 
prevention and treatment of tumor, various forms of NSAIDs 
become available for tumor prevention or treatment either 
in vivo or in vitro. One example is the use of aspirin-phos-
phatidylcholine in vitro achieved better results in human or 
murine colon cancer cell lines at the cellular level compared 
to traditional aspirin.54 In addition, another study57 showed 
that the use of nano-forms of aspirin and ibuprofen to treat 
lung cancer patient’s whole blood in vitro could effectively 
reduce the DNA damage of white blood cells, which sug-
gested that the nano-form of NSAIDs is more likely to enter 
the cell membrane and bind to DNA. It is worth mentioning 
that the use of metal complexes could also enhance the affin-
ity of the complex for DNA binding.42 Therefore, NSAIDs 
and metal complexes should be taken into consideration in 
the treatment of cancer. Compared with traditional NSAIDs, 
NSAIDs with bio-metals show better pharmacological 
activity,58 and lower gastrointestinal  toxicity.59 In addition, 
different metal and NSAIDs complexes are selective for 
different cell lines, for example, the platinum complexes of 
the NSAIDs tomeidine and indomethacin have the higher 
selectivity on non-cancerous cells BHK21 and L929.42 This 
suggests that we can choose different metal complexes as 
ligands to modify NSAIDs and to achieve selective killing 
of tumor cells.
In addition, as early as 2013, Liu et al60 conducted a meta-
analysis of 10 studies between 2003 and 2013 and concluded 
that the use of aspirin and other NSAIDs did not significantly 
affect the incidence of brain tumors and was not associated 
with special subtypes of brain tumor. However, Simms et al61 
showed that in vivo the liquid containing aspirin may be able 
to extend the life of thousands of patients with brain cancer. 
This is a breakthrough result in which they found that liquid 
aspirin can pass through the blood–brain barrier (known in 
the treatment of brain tumor, the blood–brain barrier can 
prevent chemotherapy drugs passing into the brain to kill 
brain tumor cells), and early tests showed that compared to 
existing chemotherapy drugs, liquid aspirin can kill brain 
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cancer cells to improve the efficiency ten-fold. Therefore, 
we speculate that the role of aspirin in tumor treatment may 
be associated with the use of drug forms.
Enhance the effect of antitumor therapy
Some NSAIDs can enhance the sensitivity of the tumor to 
chemotherapy drugs, thus antitumor drugs and NSAIDs 
combination can produce a better prognosis in tumor therapy. 
Huang et al62 found that for in vitro culture of glioma cells, the 
use of indomethacin and adriamycin can significantly inhibit 
tumor cell growth than indomethacin use only. The result of 
QT-PCR and Western blot showed that indomethacin could 
downregulate the expression of ABCG2, MDR1 and MRP1, 
which were colloidal tumor-associated resistance genes, so 
that the antitumor effect of chemotherapeutic drugs was 
significantly improved. In addition, indomethacin does not 
only downregulate the resistance genes, but also enhances 
the sensitivity of colon cancer cells to chemotherapy drugs. 
5-fluorouracil (5Fu) is known as a common cancer chemo-
therapy drug. Réti et al63 found that in patient body 80% 
5Fu could metabolize into 5, 6-dihydro-5-fluorouracil by 
dihydropyrimidine dehydrogenase and lost the activity. And 
taking indomethacin could increase the concentration of 
5Fu in vivo by inhibiting the activity of dihydropyrimidine 
dehydrogenase; thereby the increasing concentration of 5Fu 
can enhance the toxicity to tumor cells. Cheng et al64 demon-
strated a new technique by using nucleophilic substitution to 
combine tumor chemotherapeutic drug cisplatin and aspirin 
which can significantly reduce the drug resistance of cisplatin 
in tumor therapy. Finally, in a recent study,49 the researchers 
found that when using combination of aspirin and clopidogrel 
(antiplatelet drugs) to treat melanoma-bearing mice, the mice 
obtained longer survival and fewer relapses when receiving 
adoptive T-cell therapy, suggesting that antiplatelet drugs 
could attenuate the ability of platelets to help tumor cells 
escape immune clearance. It is fair to say that the combina-
tion of NSAIDs and traditional cancer therapies or adoptive 
T cell therapy therefore could lead to a further breakthrough 
in cancer therapy with “1+1>2.”
All the above new thoughts are summarized in Table 3.
Conclusion
Based on a large amount of clinical data, NSAIDs, especially 
aspirin chemical prophylaxis has been gradually extended to 
clinical cancer treatment. The National Comprehensive Cancer 
Network colorectal cancer guide (2017 version) established the 
role of aspirin in the secondary prevention of cancer. However, 
taking into account the side effects of long-term use of aspirin, 
the large-scale use of aspirin as a cancer chemical prophylaxis 
still needs to weigh up the pros and cons for individual patients. 
The US “Guidelines for the Use of Preventive Drugs” clearly 
state that daily intake of “low-dose” aspirin has anticancer 
effects; here “low-dose” means 75–100 mg per day. But it is 
worth noting that the mechanism of anti-inflammatory drugs 
in tumor prevention and control is still not clear, future stud-
ies need to focus on the precise molecular classification and 
Table 3 The new thinking about NSAIDs inhibiting tumors
NSAIDs Target Target function Interaction
Aspirin PGE248 Attenuate the immune system’s normal response to 
diseased cells and help cancer cells to hide
Inhibit the synthesis of PGE2
Aspirin Platelets49,52–54 In vivo platelet-derived or non-platelet-derived TGFβ 
and GARP complex can effectively reduce the activity 
of T-cell activity
Inhibit the activity of COX-1 enzyme, 
control the number of circulating 
platelets and their activity levels
Platelets spontaneously recruited help the tumor 
growth, enhance the invasiveness, promote EMT 
transformation
Aspirin Genetic mutations56 Tumorigenesis is caused by long-term accumulation of 
genetic mutations
Slow down gene mutation accumulation 
and protect normal cell DNA
DNA damage42,57 Gene damage increases the chance of DNA sequence 
changes
Aspirin/ 
Indomethacin
Traditional 
chemotherapy drugs 
therapy62–64
Direct killing of tumor cells by multiple ways Increase drug toxicity and downregulate 
cellular drug resistance
Adoptive T-cell therapy49 Organism’s own T cells are propagated in vitro and 
chosen specifically to recognize tumor cells. The 
culture is expanded and then returned to the cancer 
patients
Attenuate the ability of platelets to help 
tumor cells escape immune clearance
Abbrevations: GARP, Glycoprotein A Repetitions Predominant; NSAIDs, nonsteroidal anti-inflammatory drugs; PGE2, prostaglandin E2.
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reasonable choice of population and dose, to achieve the largest 
anticancer benefits. As the body’s own platelets are linked to 
tumor growth and metastasis during tumorigenesis,54 our in 
vitro study found that platelets promote the proliferation of 
tumor cells and this effect can be inhibited by aspirin (unpub-
lished data). In addition, a prospective cohort study50 showed 
that thrombocytosis is positively associated with tumor inci-
dence. Of all the 9,435 male thrombocythemia patients, 1,098 
were diagnosed with cancer (11.6%; 95% CI=11.0–12.3), 
however, only 106 out of 2,599 men without thrombocytosis 
had cancer (4.1%; 95% CI=3.4–4.9). Similarly, a total of 1,355 
out of 21,826 females with thrombocytosis developed cancer 
(6.2%; 95% CI=5.9–6.5), compared with 119 of 5,370 females 
without (2.2%; 95% CI=1.8–2.6). Our previous in vitro stud-
ies also showed that the effect of platelets on adenoma cells 
is two-sided, but this effect can be attenuated by the platelet 
antagonist aspirin (unpublished data). Furthermore, our in 
vivo experiments have shown that aspirin has a certain effect 
on inhibiting tumor metastasis and both the duration and 
varying time periods of drug use could affect the survival of 
tumor-bearing mice (unpublished data). Further research work 
should focus on exploring the relationship between platelet, 
cancer and aspirin, clarifying the role of platelets in tumori-
genesis and development, evaluating which stage of aspirin 
intervention could gain more benefits, proposing potential 
molecular mechanisms and new ideas for aspirin in clinical 
cancer prevention and treatment.
Disclosure
The authors report no conflicts of interest in this work.
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